Merck adds another OK to Keytruda scoreboard; Ardelyx, Kyowa Kirin broadens partnership beyond tenapanor
→ Merck‘s anti-PD-1 blockbuster, Keytruda, is racking up win after win. The newest jewel to the crown for the company is the Chinese approval of the therapy in combination with carboplatin and paclitaxel for the first-line cases of metastatic squamous non-small cell lung cancer (NSCLC). With this new indication, Keytruda is now approved to treat both squamous and non-squamous NSCLC in conjunction with chemotherapy, as well as a subgroup of NSCLC patients as a monotherapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.